In 2016, a clinical trial was set up in order to evaluate the clinical benefit of combining pembrolizumab and imatinib in patients with locally advanced/metastatic melanoma harboring c-KIT Mutation/Amplification (NCT02812693), but unfortunately, the trial was withdrawn due to poor accrual [52]. Here, KIT is linked to metastatic melanoma.